Jazz Turns Attention To Narcolepsy In 2011
This article was originally published in The Pink Sheet Daily
The specialty pharma has shifted its focus from pursuit of a fibromyalgia indication for JZP-6 to Xyrem for narcolepsy.
You may also be interested in...
Jazz Pharmaceuticals will likely have to narrow the proposed indication for its fibromyalgia drug JZP-6 (sodium oxybate) following a "complete response" letter from FDA, but that appears to be only the first step for the product.
Jazz's reformulation of sodium oxybate for fibromyalgia ran into advisory committee skepticism last week, but at least one analyst predicts FDA will override the 20-2 negative vote.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.